IRIS
BODINI, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.302
NA - Nord America 1.628
AS - Asia 1.573
Continente sconosciuto - Info sul continente non disponibili 456
SA - Sud America 129
AF - Africa 29
OC - Oceania 4
Totale 15.121
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 10.992
US - Stati Uniti d'America 1.511
SG - Singapore 547
CN - Cina 393
VN - Vietnam 264
BD - Bangladesh 196
FR - Francia 115
BR - Brasile 71
HK - Hong Kong 56
CA - Canada 55
DE - Germania 41
FI - Finlandia 39
GB - Regno Unito 37
AR - Argentina 25
MX - Messico 23
JP - Giappone 21
ID - Indonesia 20
NL - Olanda 17
IN - India 16
EC - Ecuador 12
IQ - Iraq 12
JM - Giamaica 9
CR - Costa Rica 8
PH - Filippine 8
UA - Ucraina 8
CL - Cile 7
TR - Turchia 7
CH - Svizzera 6
KE - Kenya 6
RU - Federazione Russa 6
ZA - Sudafrica 6
CO - Colombia 5
ES - Italia 5
JO - Giordania 5
VE - Venezuela 5
AU - Australia 4
IE - Irlanda 4
NI - Nicaragua 4
SE - Svezia 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
DZ - Algeria 3
ET - Etiopia 3
NP - Nepal 3
PL - Polonia 3
PT - Portogallo 3
SA - Arabia Saudita 3
XK - ???statistics.table.value.countryCode.XK??? 3
AT - Austria 2
BA - Bosnia-Erzegovina 2
BZ - Belize 2
CZ - Repubblica Ceca 2
GT - Guatemala 2
HN - Honduras 2
IL - Israele 2
KR - Corea 2
LB - Libano 2
LC - Santa Lucia 2
LT - Lituania 2
LV - Lettonia 2
MA - Marocco 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
RO - Romania 2
RS - Serbia 2
TH - Thailandia 2
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BY - Bielorussia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GA - Gabon 1
GG - Guernsey 1
GP - Guadalupe 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
KH - Cambogia 1
LY - Libia 1
MD - Moldavia 1
ML - Mali 1
MY - Malesia 1
PA - Panama 1
PR - Porto Rico 1
SC - Seychelles 1
SI - Slovenia 1
SV - El Salvador 1
TW - Taiwan 1
Totale 14.668
Salva come PNG Salva come JPEG
Città #
Genova 5.160
Genoa 3.875
Vado Ligure 928
Rapallo 771
San Jose 329
Singapore 226
Ashburn 222
Lauterbourg 103
Council Bluffs 99
Ho Chi Minh City 81
Beijing 72
New York 69
Hanoi 60
Hong Kong 54
Santa Clara 43
Los Angeles 35
Helsinki 32
Frankfurt am Main 31
Milan 29
Boardman 26
Orem 25
Rome 20
Tokyo 18
Bordighera 17
Buffalo 17
Chicago 17
Phoenix 16
Mexico City 15
Da Nang 12
Amsterdam 11
Dallas 11
São Paulo 11
Toronto 11
Montreal 10
Philadelphia 10
Naples 9
Poplar 9
Tianjin 9
Atlanta 8
Charlotte 8
San José 8
Washington 8
Bologna 7
Haiphong 7
Lappeenranta 7
London 7
Seattle 7
Baghdad 6
Columbus 6
Memphis 6
Mumbai 6
Ninh Bình 6
The Bronx 6
Zurich 6
Amman 5
Cardiff 5
City of London 5
Denver 5
Des Moines 5
Dublin 5
Hamilton 5
Houston 5
Kingston 5
Manchester 5
Nairobi 5
Newark 5
Queens 5
San Francisco 5
Boston 4
Brescia 4
Bắc Ninh 4
Can Tho 4
Charleston 4
Cleveland 4
Florence 4
Guangzhou 4
Hải Dương 4
Iowa City 4
Jacksonville 4
Kyiv 4
Miami 4
Milwaukee 4
Minneapolis 4
Modena 4
Orlando 4
Portland 4
Quảng Ngãi 4
Sacramento 4
Santiago 4
Shanghai 4
Stockholm 4
Tashkent 4
Vancouver 4
Venice 4
Wesley Chapel 4
Addis Ababa 3
Beachwood 3
Biên Hòa 3
Brasília 3
Brooklyn 3
Totale 12.795
Salva come PNG Salva come JPEG
Nome #
Proton pump inhibitors: use and misuse in the clinical setting 249
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 223
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 215
Advancements in the use of manometry and impedance testing for esophageal functional disorders 210
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 206
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 204
A safety review of proton pump inhibitors to treat acid-related digestive diseases 202
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 200
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 198
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 193
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 181
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases 173
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 173
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 171
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. 170
A Nodule, is a Nodule, is a Nodule: May Alpha-fetoprotein Make the Difference? 170
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations 169
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 168
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 168
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 167
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 165
The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin 165
Letter: Biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease 162
The appropriate use of proton-pump inhibitors 162
Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases
 162
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. 161
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 161
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 160
Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease? 160
Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients 160
Optimal management of constipation associated with irritable bowel syndrome. 158
A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease 156
The natural history of gastro-esophageal reflux disease: A comprehensive review 155
Epidemiology and natural history of gastroesophageal reflux disease 153
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies 148
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 143
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio 143
Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis 142
Tryciclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients? 140
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 140
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 139
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. 138
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 137
Gastrointestinal involvement in systemic sclerosis 137
Concerns related to COVID-19 pandemic among patients with Inflammatory Bowel Disease, and its influence on patients management 136
The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. 135
Prevention of Crohn's disease recurrence after surgery: on the road to recovery. 135
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? 131
Esophageal motility abnormalities in gastroesophageal reflux disease 131
Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study 131
Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study 130
Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease 128
Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. 127
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients 127
Esophageal testing: What we have so far 126
M01822 Diagnostic accuracy and Inter/Intra-observer Agreement between endoscopists with different expertise, before and after a short training, for the detection of gastric intestinal metaplasia by means of narrow band imaging with magnifying endoscopy 125
Reproducibility and transportability of the absence of incremental infectious adverse events in patients with higher anti-TNF drug levels 125
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV 125
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 122
Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. 122
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 122
Autoimmune chronic atrophic gastritis: association between chronic proton pump inhibitors use and more severe atrophy and gastric intestinal metaplasia 121
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 120
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis 119
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data 118
DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN'S DISEASE BASED ON SERUM LEVELS OF PROTEINS 118
High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in vivo evaluation 117
Institution of an interdisciplinary IBD centre is associated with improved healthcare utilisation 116
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients 115
Esophageal motor disorders across ages: A retrospective multicentric analysis 112
Vegetal and animal food proteins have a different impact in the first postprandial hour of impedance-pH analysis in patients with heartburn 112
Vonoprazan fumarate for the management of acid-related diseases 112
Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I 110
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose 109
Treatment of early stage chronic hepatitis C virus infection 109
Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment 109
Letter: Biological therapies are effective for prevention of post-operative Crohn's disease recurrence 108
Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease 105
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 104
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand 104
The Lyon Consensus: Does it differ from the previous ones? 104
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 99
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques 99
Effect of hiatal hernia and esophagogastric junction morphology on esophageal motility: Evidence from high‐resolution manometry studies 97
Prospective evaluation on the prevalence of serrated adenoma during a two-year period in an italian endoscopy centre 96
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD 96
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 96
Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study 94
Intra- and interobserver Agreement between endoscopists and pathologists for detection of gastric intestinal metaplasia by means of narrow band imaging with magnifying endoscopy 92
Albumin-bilirubin score in non-malignant liver diseases should be properly validated 90
Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. 89
Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand 87
The crohn's disease exclusion diet in adults with mild-to-moderate crohn’s disease activity: A real-world open-label randomized controlled trial 86
Food Intolerances, Food Allergies and IBS: Lights and Shadows 85
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 84
Clopidogrel-Induced Eosinophilic Colitis 83
Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission 82
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility 82
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 81
Diagnostic delay in achalasia 81
Totale 13.576
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.728
article - articoli 52.728
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.033 72 34 53 83 35 114 38 238 79 117 51 119
2022/2023963 111 100 14 64 155 118 7 84 166 7 121 16
2023/2024804 28 80 12 106 72 144 64 29 31 35 73 130
2024/20252.427 106 145 116 132 302 269 177 433 104 92 252 299
2025/20264.990 511 211 449 435 538 355 633 219 398 513 306 422
2026/2027463 463 0 0 0 0 0 0 0 0 0 0 0
Totale 15.121